Skip to main content

Market Overview

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

  • Innate Pharma SA's (NASDAQ: IPHA) ongoing TELLOMAK Phase 2 trial, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit additional patients. The company expects to present the preliminary data from this cohort at a scientific meeting this year. The study is expected to recruit up to 150 patients.
  • Recruitment in cohort 3 is ongoing, evaluating lacutamab as monotherapy in KIR3DL2 non-expressing mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma.
  • The company also plans to initiate two parallel trials to evaluate lacutamab in KIR3DL2-expressing patients with relapsed/refractory peripheral T-cell lymphoma, including a Company-sponsored Phase 1b trial to evaluate lacutamab as monotherapy in KIR3DL2-expressing patients with relapsed PTCL, and an investigator-sponsored trial to evaluate lacutamab in combination with chemotherapy GEMOX, versus GEMOX alone in KIR3DL2-expressing relapsed/refractory patients.
  • Webcast and conference call is scheduled for 8:00 a.m. ET today.
  • Price Action: IPHA shares closed 5.5% higher at $4.63 on Monday.

Related Articles (IPHYF + IPHA)

View Comments and Join the Discussion!

Posted-In: blood cancer Phase 2Biotech News Penny Stocks Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at